We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Updates Advice on Evaluating Common Symptoms in Outpatient COVID-19 Trials
FDA Updates Advice on Evaluating Common Symptoms in Outpatient COVID-19 Trials
The FDA has issued a new final guidance on assessing COVID-19-related symptoms in drug and biologics trials for outpatient prevention/treatment of the infectious disease, overriding its prior recommendations from September 2020.